The U.S. Food and Drug Administration has approved a higher, 2 milligram dose of the injectable medication semaglutide for chronic weight management, a decision that provides a new option for adults struggling with obesity or excess weight. The approval was granted under the agency's accelerated review pathway, reflecting the significant need for effective weight-loss therapies.
The newly approved dose builds upon the existing 1 mg and lower-dose formulations. Clinical trials demonstrated that the 2 mg dose of semaglutide led to greater average weight reduction compared to the lower doses. In one key study, participants receiving the higher dose achieved an average weight loss of approximately 15% of their body weight over a 68-week period, when combined with lifestyle interventions. The medication works by mimicking a hormone that targets areas of the brain involved in appetite regulation and food intake, helping patients feel fuller for longer and reducing calorie consumption.
This approval is specifically for adults with a body mass index of 30 or greater, or 27 or greater if they have at least one weight-related condition such as high blood pressure, type 2 diabetes, or elevated cholesterol. For patients who have plateaued on lower doses, the higher strength offers a new avenue to continue their weight management journey. The most common side effects reported align with those of similar medications and include gastrointestinal symptoms such as nausea and diarrhea, which are often temporary.
Looking ahead, the availability of a higher-dose option marks a progressive step in the medical management of obesity, a condition affecting tens of millions of Americans. Medical experts anticipate that this could help a broader range of patients achieve more substantial and sustained weight loss goals. Continued monitoring and post-approval studies will further solidify the long-term safety and efficacy profile of this treatment, offering renewed hope for those seeking effective tools to improve their metabolic health.